Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Orexin Receptor Type 1 Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 5:14
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Pipeline Review, H2 2016’, provides in depth analysis on Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711795-orexin-receptor-type-1-hypocretin-receptor-type-1-or-hcrtr1-pipeline-review-h2-2016

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) 
- The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Complete report details @ https://www.wiseguyreports.com/reports/711795-orexin-receptor-type-1-hypocretin-receptor-type-1-or-hcrtr1-pipeline-review-h2-2016      

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 5 
Introduction 6 
Report Coverage 6 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Overview 7 
Therapeutics Development 8 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Products under Development by Stage of Development 8 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Products under Development by Therapy Area 9 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Products under Development by Indication 10 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Pipeline Products Glance 11 
Late Stage Products 11 
Early Stage Products 12 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Products under Development by Companies 13 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Therapeutics Assessment 15 
Assessment by Monotherapy/Combination Products 15 
Assessment by Mechanism of Action 16 
Assessment by Route of Administration 17 
Assessment by Molecule Type 18 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Companies Involved in Therapeutics Development 19 
Actelion Ltd 19 
C4X Discovery Holdings PLC 20 
Eisai Co., Ltd. 21 
Hager Biosciences, LLC 22 
Heptares Therapeutics Limited 23 
Merck & Co., Inc. 24 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Drug Profiles 25 
DORA-12 – Drug Profile 25 
Product Description 25 
Mechanism Of Action 25 
R&D Progress 25 
EORA-101 – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
HTL-6641 – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
lemborexant – Drug Profile 28 
Product Description 28 
Mechanism Of Action 28 
R&D Progress 28 
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
Small Molecule to Antagonize Orexin Receptor Type 1 for Neurology – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
Small Molecules to Antagonize Orexin-1 Receptor for Addiction – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
suvorexant – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Dormant Projects 39 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Discontinued Products 40 
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Featured News & Press Releases 41 
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia 41 
May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development 42 
Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 43 
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 43 
Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 45 
Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 45 
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 47 
May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 48 
May 20, 2013: Merck’s Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 48 
Apr 03, 2013: Merck’s Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 49 
Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 49 
Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 50 
Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 50 
Jun 13, 2012: Merck Announces New Positive Data From Two Pivotal Phase III Efficacy Trials Of Suvorexant For Treatment Of Insomnia 52 
Feb 06, 2012: Merck Provides Update On Development Program For Investigational Insomnia Drug, Suvorexant 54 
Appendix 55 
Methodology 55 
Coverage 55 
Secondary Research 55 
Primary Research 55 
Expert Panel Validation 55 
Contact Us 55 
Disclaimer 56

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711795

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.